| 0.63 | 0.005 | 0.63 | GABA C receptor rho-3 antagonist | | |
| 0.609 | 0.006 | 0.609 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | | |
| 0.597 | 0.003 | 0.597 | Porphobilinogen synthase inhibitor | | |
| 0.554 | 0.006 | 0.554 | Peroxidase inhibitor | | |
| 0.511 | 0.025 | 0.511 | 5 Hydroxytryptamine release stimulant | | |
| 0.497 | 0.033 | 0.497 | Aldehyde oxidase inhibitor | | |
| 0.511 | 0.056 | 0.511 | Caspase 9 stimulant | | |
| 0.481 | 0.039 | 0.481 | 5 Hydroxytryptamine release inhibitor | | |
| 0.441 | 0.004 | 0.441 | Hedgehog signaling inhibitor | | |
| 0.46 | 0.045 | 0.46 | Histamine release inhibitor | | |
| 0.438 | 0.039 | 0.438 | MAP kinase kinase 6 inhibitor | | |
| 0.404 | 0.023 | 0.404 | Calcium channel activator | | |
| 0.393 | 0.028 | 0.393 | Superoxide dismutase inhibitor | | |
| 0.356 | 0.005 | 0.356 | Nitric-oxide synthase stimulant | | |
| 0.38 | 0.041 | 0.38 | Aryl hydrocarbon receptor agonist | | |
| 0.374 | 0.044 | 0.374 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | | |
| 0.4 | 0.081 | 0.4 | Calcium channel L-type activator | | |
| 0.318 | 0.006 | 0.318 | Ferrochelatase inhibitor | | |
| 0.34 | 0.037 | 0.34 | Pyruvate kinase inhibitor | | |
| 0.293 | 0.006 | 0.293 | GABA C receptor rho-2 antagonist | | |
| 0.286 | 0.005 | 0.286 | Activin receptor-like kinase 4 inhibitor | | |
| 0.284 | 0.004 | 0.284 | CYP2A6 inhibitor | | |
| 0.295 | 0.019 | 0.295 | Neurotrophic factor enhancer | | |
| 0.314 | 0.038 | 0.314 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.279 | 0.004 | 0.279 | Smo receptor antagonist | | |
| 0.341 | 0.068 | 0.341 | Cholesterol antagonist | | |
| 0.302 | 0.031 | 0.302 | Gastrin inhibitor | | |
| 0.297 | 0.034 | 0.297 | Anesthetic general | | |
| 0.267 | 0.005 | 0.267 | Gastric antisecretory | | |
| 0.271 | 0.009 | 0.271 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.281 | 0.02 | 0.281 | Growth factor agonist | | |
| 0.272 | 0.022 | 0.272 | NOS3 expression enhancer | | |
| 0.3 | 0.059 | 0.3 | Insulysin inhibitor | | |
| 0.282 | 0.043 | 0.282 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.282 | 0.043 | 0.282 | Tyrosine 3 hydroxylase inhibitor | | |
| 0.25 | 0.012 | 0.25 | Mannose-6-phosphate isomerase inhibitor | | |
| 0.257 | 0.022 | 0.257 | Alpha-N-acetylglucosaminidase inhibitor | | |
| 0.319 | 0.088 | 0.319 | Vasodilator, peripheral | | |
| 0.267 | 0.041 | 0.267 | RNA-directed DNA polymerase inhibitor | | |
| 0.253 | 0.028 | 0.253 | Protein kinase (CK1) gamma 1 inhibitor | | |
| 0.253 | 0.029 | 0.253 | MAP kinase kinase 3 inhibitor | | |
| 0.25 | 0.029 | 0.25 | Cytidine deaminase inhibitor | | |
| 0.221 | 0.004 | 0.221 | H+/K+-transporting ATPase inhibitor | | |
| 0.221 | 0.012 | 0.221 | Beta amyloid protein antagonist | | |
| 0.24 | 0.032 | 0.24 | 3C-like protease (Human coronavirus) inhibitor | | |
| 0.252 | 0.044 | 0.252 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | | |
| 0.238 | 0.031 | 0.238 | Histone acetyltransferase inhibitor | | |
| 0.223 | 0.017 | 0.223 | GABA C receptor agonist | | |
| 0.275 | 0.071 | 0.275 | Transcription factor STAT inhibitor | | |
| 0.237 | 0.033 | 0.237 | Protein kinase (CK1) gamma inhibitor | | |
| 0.259 | 0.059 | 0.259 | Cyclic AMP phosphodiesterase inhibitor | | |
| 0.269 | 0.074 | 0.269 | Ca(v)3.3 blocker | | |
| 0.201 | 0.008 | 0.201 | GABA C receptor rho-1 antagonist | | |
| 0.255 | 0.064 | 0.255 | Potassium channel blocker | | |
| 0.197 | 0.007 | 0.197 | Transcription factor STAT6 inhibitor | | |
| 0.251 | 0.064 | 0.251 | Ca2+/calmodulin-dependent kinase IV inhibitor | | |
| 0.199 | 0.013 | 0.199 | GABA C receptor antagonist | | |
| 0.212 | 0.029 | 0.212 | Hexokinase inhibitor | | |
| 0.331 | 0.149 | 0.331 | MAP kinase 1 inhibitor | | |
| 0.211 | 0.029 | 0.211 | Protein kinase (CK1) gamma 2 inhibitor | | |
| 0.285 | 0.103 | 0.285 | Transcription factor NF kappa B inhibitor | | |
| 0.191 | 0.011 | 0.191 | Glutamate (mGluR) antagonist | | |
| 0.203 | 0.025 | 0.203 | Glutamate receptor antagonist | | |
| 0.186 | 0.009 | 0.186 | Glutamate (mGluR group I) antagonist | | |
| 0.219 | 0.043 | 0.219 | Tumour necrosis factor antagonist | | |
| 0.193 | 0.017 | 0.193 | 5 Hydroxytryptamine 3A agonist | | |
| 0.183 | 0.007 | 0.183 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | | |
| 0.226 | 0.051 | 0.226 | Focal adhesion kinase 2 inhibitor | | |
| 0.267 | 0.093 | 0.267 | Streptokinase A inhibitor | | |
| 0.187 | 0.014 | 0.187 | TRPA1 agonist | | |
| 0.224 | 0.052 | 0.224 | LIM domain kinase 1 inhibitor | | |
| 0.195 | 0.025 | 0.195 | CF transmembrane conductance regulator agonist | | |
| 0.176 | 0.009 | 0.176 | Ca2+-transporting ATPase inhibitor | | |
| 0.2 | 0.035 | 0.2 | Cyclin-dependent kinase 8 inhibitor | | |
| 0.189 | 0.025 | 0.189 | Antibacterial (Helicobacter pylori) | | |
| 0.172 | 0.009 | 0.172 | Phenylalanine 4-hydroxylase inhibitor | | |
| 0.238 | 0.075 | 0.238 | DNA synthesis inhibitor | | |
| 0.221 | 0.058 | 0.221 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | | |
| 0.171 | 0.009 | 0.171 | Histamine N-methyltransferase inhibitor | | |
| 0.169 | 0.008 | 0.169 | Biliverdin reductase inhibitor | | |
| 0.168 | 0.009 | 0.168 | Acetylcholine release stimulant | | |
| 0.216 | 0.058 | 0.216 | I kappa B kinase epsilon inhibitor | | |
| 0.177 | 0.021 | 0.177 | Pregnane X receptor agonist | | |
| 0.203 | 0.047 | 0.203 | Heat shock protein 90 alpha antagonist | | |
| 0.184 | 0.029 | 0.184 | Cystathionine beta-synthase inhibitor | | |
| 0.202 | 0.047 | 0.202 | Succinate dehydrogenase inhibitor | | |
| 0.161 | 0.006 | 0.161 | Bromodomain-containing protein 2 inhibitor | | |
| 0.176 | 0.022 | 0.176 | UDP-glucose 4-epimerase inhibitor | | |
| 0.269 | 0.115 | 0.269 | Vasodilator, coronary | | |
| 0.24 | 0.086 | 0.24 | DNA damaging | | |
| 0.185 | 0.032 | 0.185 | Aldehyde dehydrogenase inhibitor | | |
| 0.157 | 0.005 | 0.157 | Transforming growth factor antagonist | | |
| 0.155 | 0.005 | 0.155 | Potassium channel (ATP-sensitive) blocker | | |
| 0.162 | 0.015 | 0.162 | NADH dehydrogenase inhibitor | | |
| 0.218 | 0.071 | 0.218 | MAP kinase kinase 2 inhibitor | | |
| 0.156 | 0.01 | 0.156 | Purinergic P2X2 antagonist | | |
| 0.172 | 0.026 | 0.172 | GABA receptor agonist | | |
| 0.208 | 0.064 | 0.208 | CDC-like kinase 4 inhibitor | | |
| 0.175 | 0.031 | 0.175 | Nav1.6 sodium channel blocker | | |
| 0.189 | 0.045 | 0.189 | Interferon gamma antagonist | | |
| 0.153 | 0.01 | 0.153 | Alcohol oxidase inhibitor | | |
| 0.19 | 0.047 | 0.19 | ATPase inhibitor | | |
| 0.187 | 0.046 | 0.187 | Death-associated protein kinase 2 inhibitor | | |
| 0.18 | 0.04 | 0.18 | Cell wall synthesis inhibitor | | |
| 0.146 | 0.006 | 0.146 | Granulocyte macrophage colony stimulating factor agonist | | |
| 0.167 | 0.028 | 0.167 | MAP kinase kinase kinase inhibitor | | |
| 0.295 | 0.157 | 0.295 | Transcription factor inhibitor | | |
| 0.145 | 0.009 | 0.145 | Nicotinic alpha4beta2 receptor antagonist | | |
| 0.185 | 0.049 | 0.185 | Amylase inhibitor | | |
| 0.141 | 0.005 | 0.141 | Glutamate (mGluR5) antagonist | | |
| 0.18 | 0.047 | 0.18 | Activin receptor-like kinase 2 inhibitor | | |
| 0.147 | 0.015 | 0.147 | Macrophage colony-stimulating factor 1 receptor antagonist | | |
| 0.158 | 0.027 | 0.158 | Photosensitizer | | |
| 0.182 | 0.051 | 0.182 | Arachidonic acid antagonist | | |
| 0.153 | 0.023 | 0.153 | Creatine kinase inhibitor | | |
| 0.201 | 0.071 | 0.201 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | | |
| 0.153 | 0.026 | 0.153 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | | |
| 0.17 | 0.043 | 0.17 | MAP kinase 3 inhibitor | | |
| 0.173 | 0.047 | 0.173 | Hemostatic | | |
| 0.146 | 0.021 | 0.146 | Alcohol dehydrogenase inhibitor | | |
| 0.156 | 0.034 | 0.156 | Heat shock protein 70 antagonist | | |
| 0.24 | 0.117 | 0.24 | Nootropic | | |
| 0.207 | 0.085 | 0.207 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | | |
| 0.166 | 0.045 | 0.166 | Toll-Like receptor antagonist | | |
| 0.16 | 0.04 | 0.16 | Cathepsin H inhibitor | | |
| 0.125 | 0.005 | 0.125 | Orexin receptor 1 antagonist | | |
| 0.151 | 0.033 | 0.151 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | | |
| 0.151 | 0.033 | 0.151 | Sphingosine 1-phosphate receptor 4 antagonist | | |
| 0.268 | 0.151 | 0.268 | 15-Lipoxygenase inhibitor | | |
| 0.136 | 0.018 | 0.136 | Lanosterol 14 alpha demethylase inhibitor | | |
| 0.137 | 0.021 | 0.137 | Glutamate receptor agonist | | |
| 0.122 | 0.006 | 0.122 | Orexin receptor antagonist | | |
| 0.16 | 0.045 | 0.16 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.202 | 0.087 | 0.202 | EphB2 antagonist | | |
| 0.138 | 0.024 | 0.138 | Triose-phosphate isomerase inhibitor | | |
| 0.145 | 0.03 | 0.145 | CC chemokine 6 receptor antagonist | | |
| 0.134 | 0.019 | 0.134 | GABA A receptor agonist | | |
| 0.132 | 0.018 | 0.132 | CXC chemokine 4 receptor antagonist | | |
| 0.17 | 0.057 | 0.17 | Protein-tyrosine kinase Lyn inhibitor | | |
| 0.142 | 0.029 | 0.142 | Beta glucuronidase inhibitor | | |
| 0.119 | 0.006 | 0.119 | S-adenosyl-L-methionine decarboxylase inhibitor | | |
| 0.13 | 0.018 | 0.13 | Phosphodiesterase 6D inhibitor | | |
| 0.137 | 0.025 | 0.137 | Electrolyte absorption antagonist | | |
| 0.16 | 0.048 | 0.16 | Adenylate cyclase stimulant | | |
| 0.118 | 0.008 | 0.118 | Aryl hydrocarbon receptor antagonist | | |
| 0.139 | 0.031 | 0.139 | Adenylate kinase inhibitor | | |
| 0.112 | 0.004 | 0.112 | Chemokine receptor agonist | | |
| 0.116 | 0.009 | 0.116 | Phosphodiesterase 10A inhibitor | | |
| 0.116 | 0.009 | 0.116 | Phosphodiesterase X inhibitor | | |
| 0.192 | 0.084 | 0.192 | Clk dual-specificity kinase inhibitor | | |
| 0.173 | 0.066 | 0.173 | Protein kinase (CK1) gamma 3 inhibitor | | |
| 0.151 | 0.044 | 0.151 | Platelet activating factor antagonist | | |
| 0.159 | 0.053 | 0.159 | Phosphodiesterase inhibitor | | |
| 0.161 | 0.056 | 0.161 | Toll-Like receptor 9 antagonist | | |
| 0.228 | 0.123 | 0.228 | 12-Lipoxygenase inhibitor | | |
| 0.169 | 0.064 | 0.169 | Neurotensin receptor agonist | | |
| 0.148 | 0.044 | 0.148 | Sphingosine 1-phosphate receptor 2 antagonist | | |
| 0.11 | 0.006 | 0.11 | Glutamate (mGluR7) antagonist | | |
| 0.13 | 0.026 | 0.13 | Stem cell growth factor agonist | | |
| 0.113 | 0.01 | 0.113 | 5 Hydroxytryptamine 3 agonist | | |
| 0.133 | 0.032 | 0.133 | DOPA decarboxylase inhibitor | | |
| 0.118 | 0.017 | 0.118 | Benzodiazepine agonist | | |
| 0.107 | 0.006 | 0.107 | Glutamate (mGluR5) agonist | | |
| 0.107 | 0.007 | 0.107 | Aconitate hydratase inhibitor | | |
| 0.14 | 0.041 | 0.14 | DNA repair enzyme inhibitor | | |
| 0.121 | 0.021 | 0.121 | Glutamate release inhibitor | | |
| 0.112 | 0.014 | 0.112 | Transforming growth factor beta 3 antagonist | | |
| 0.108 | 0.01 | 0.108 | Phospholipase D inhibitor | | |
| 0.111 | 0.014 | 0.111 | Acetylcholine M5 receptor agonist | | |
| 0.185 | 0.089 | 0.185 | Insulin sensitizer | | |
| 0.15 | 0.054 | 0.15 | Sodium channel (voltage-gated) blocker | | |
| 0.104 | 0.008 | 0.104 | Glutamate (mGluR group I) agonist | | |
| 0.1 | 0.005 | 0.1 | Glutamate (mGluR1a) antagonist | | |
| 0.129 | 0.034 | 0.129 | HIV-1 integrase (Overall Integration) inhibitor | | |
| 0.121 | 0.026 | 0.121 | Acetylcholine nicotinic agonist | | |
| 0.134 | 0.039 | 0.134 | Nav1.5 sodium channel blocker | | |
| 0.101 | 0.007 | 0.101 | Potassium channel (Inward rectifier) blocker | | |
| 0.159 | 0.065 | 0.159 | Heat shock protein 90 antagonist | | |
| 0.207 | 0.114 | 0.207 | Interleukin agonist | | |
| 0.111 | 0.019 | 0.111 | Caspase 7 inhibitor | | |
| 0.124 | 0.032 | 0.124 | MAP kinase kinase 1 inhibitor | | |
| 0.102 | 0.01 | 0.102 | Fatty acid synthase inhibitor | | |
| 0.112 | 0.022 | 0.112 | mTOR complex 2 inhibitor | | |
| 0.111 | 0.023 | 0.111 | Vanilloid 1 antagonist | | |
| 0.132 | 0.045 | 0.132 | Granulocyte macrophage colony stimulating factor antagonist | | |
| 0.163 | 0.075 | 0.163 | Src kinase inhibitor | | |
| 0.092 | 0.005 | 0.092 | Orexin receptor 2 antagonist | | |
| 0.209 | 0.122 | 0.209 | Transcription factor STAT3 inhibitor | | |
| 0.105 | 0.018 | 0.105 | Glycine receptor agonist | | |
| 0.217 | 0.132 | 0.217 | Hypoxia-inducible factor 1 alpha inhibitor | | |
| 0.103 | 0.018 | 0.103 | Phosphodiesterase VI inhibitor | | |
| 0.1 | 0.017 | 0.1 | Purinergic P2X1 antagonist | | |
| 0.131 | 0.049 | 0.131 | Interleukin 8 antagonist | | |
| 0.11 | 0.028 | 0.11 | Histidine decarboxylase inhibitor | | |
| 0.116 | 0.034 | 0.116 | Leucine-rich repeat kinase 2 inhibitor | | |
| 0.102 | 0.02 | 0.102 | CC chemokine 5 receptor agonist | | |
| 0.094 | 0.012 | 0.094 | Exportin-1 inhibitor | | |
| 0.12 | 0.038 | 0.12 | Prolactin inhibitor | | |
| 0.139 | 0.058 | 0.139 | Death-associated protein kinase 1 inhibitor | | |
| 0.114 | 0.033 | 0.114 | Platelet growth factor antagonist | | |
| 0.092 | 0.012 | 0.092 | Toll-Like receptor 8 antagonist | | |
| 0.119 | 0.039 | 0.119 | Nitric-oxide synthase inhibitor | | |
| 0.117 | 0.038 | 0.117 | Interleukin 1 beta converting enzyme inhibitor | | |
| 0.09 | 0.01 | 0.09 | Transcription factor RelA inhibitor | | |
| 0.138 | 0.059 | 0.138 | MAP kinase kinase inhibitor | | |
| 0.09 | 0.01 | 0.09 | Corticotropin releasing factor 2 receptor antagonist | | |
| 0.114 | 0.036 | 0.114 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | | |
| 0.135 | 0.057 | 0.135 | TRKA antagonist | | |
| 0.121 | 0.044 | 0.121 | Platelet activating factor alpha antagonist | | |
| 0.145 | 0.068 | 0.145 | Lck kinase inhibitor | | |
| 0.095 | 0.018 | 0.095 | Glutamate (mGluR1) antagonist | | |
| 0.109 | 0.033 | 0.109 | NAD(P)H dehydrogenase (quinone) inhibitor | | |
| 0.11 | 0.034 | 0.11 | Alpha 2d adrenoreceptor antagonist | | |
| 0.088 | 0.013 | 0.088 | Transforming growth factor beta 1 antagonist | | |
| 0.089 | 0.014 | 0.089 | Phosphodiesterase II inhibitor | | |
| 0.108 | 0.033 | 0.108 | Vanilloid antagonist | | |
| 0.088 | 0.015 | 0.088 | Phosphodiesterase 1C inhibitor | | |
| 0.103 | 0.031 | 0.103 | Fibroblast growth factor 3 antagonist | | |
| 0.123 | 0.051 | 0.123 | Aminopeptidase B inhibitor | | |
| 0.141 | 0.069 | 0.141 | Cytokine production inhibitor | | |
| 0.119 | 0.047 | 0.119 | Interleukin 2 antagonist | | |
| 0.129 | 0.058 | 0.129 | Aurora-B kinase inhibitor | | |
| 0.118 | 0.047 | 0.118 | Urease inhibitor | | |
| 0.096 | 0.026 | 0.096 | Neuronal nicotinic receptor antagonist | | |
| 0.076 | 0.005 | 0.076 | Geranyltranstransferase inhibitor | | |
| 0.089 | 0.019 | 0.089 | GABA A receptor antagonist | | |
| 0.101 | 0.031 | 0.101 | Phosphofructokinase-1 inhibitor | | |
| 0.106 | 0.036 | 0.106 | Acetylcholine nicotinic antagonist | | |
| 0.092 | 0.023 | 0.092 | Secretase beta inhibitor | | |
| 0.125 | 0.056 | 0.125 | Microtubule formation inhibitor | | |
| 0.073 | 0.005 | 0.073 | Nerve growth factor antagonist | | |
| 0.216 | 0.147 | 0.216 | Prostaglandin dehydrogenase inhibitor | | |
| 0.103 | 0.034 | 0.103 | Inducible nitric-oxide synthase inhibitor | | |
| 0.157 | 0.089 | 0.157 | CDC-like kinase 2 inhibitor | | |
| 0.084 | 0.016 | 0.084 | Fibroblast growth factor 4 antagonist | | |
| 0.076 | 0.009 | 0.076 | Pregnane X receptor antagonist | | |
| 0.13 | 0.062 | 0.13 | TRKB antagonist | | |
| 0.114 | 0.047 | 0.114 | Fibroblast growth factor 1 antagonist | | |
| 0.098 | 0.032 | 0.098 | Glutamate dehydrogenase inhibitor | | |
| 0.098 | 0.032 | 0.098 | D-Ala-D-Ala ligase inhibitor | | |
| 0.171 | 0.105 | 0.171 | Platelet aggregation inhibitor | | |
| 0.11 | 0.044 | 0.11 | Protein kinase C delta inhibitor | | |
| 0.08 | 0.014 | 0.08 | Phosphodiesterase 2A inhibitor | | |
| 0.075 | 0.009 | 0.075 | TRPM8 blocker | | |
| 0.096 | 0.03 | 0.096 | Aminopeptidase I inhibitor | | |
| 0.252 | 0.186 | 0.252 | Alpha-glucosidase inhibitor | | |
| 0.084 | 0.02 | 0.084 | GABA receptor antagonist | | |
| 0.071 | 0.007 | 0.071 | Cytokine production stimulant | | |
| 0.093 | 0.029 | 0.093 | Sphingosine 1-phosphate receptor 4 agonist | | |
| 0.086 | 0.022 | 0.086 | Potassium channel (Tandem pore domain) blocker | | |
| 0.08 | 0.017 | 0.08 | Potassium channel intermediate-conductance Ca-activated blocker | | |
| 0.084 | 0.021 | 0.084 | Alpha 2 adrenoreceptor agonist | | |
| 0.096 | 0.033 | 0.096 | Keratolytic | | |
| 0.111 | 0.049 | 0.111 | Anabolic | | |
| 0.067 | 0.006 | 0.067 | Guanylate cyclase inhibitor | | |
| 0.088 | 0.027 | 0.088 | MAP kinase kinase 7 inhibitor | | |
| 0.119 | 0.058 | 0.119 | DNA intercalator | | |
| 0.09 | 0.028 | 0.09 | Fibroblast growth factor 2 antagonist | | |
| 0.078 | 0.017 | 0.078 | Phosphodiesterase 1A inhibitor | | |
| 0.081 | 0.02 | 0.081 | 5 Hydroxytryptamine 5 antagonist | | |
| 0.147 | 0.086 | 0.147 | Melanin inhibitor | | |
| 0.065 | 0.004 | 0.065 | Vanilloid 3 antagonist | | |
| 0.069 | 0.009 | 0.069 | Dopamine beta hydroxylase inhibitor | | |
| 0.071 | 0.01 | 0.071 | Immunoglobulin Fc receptor antagonist | | |
| 0.102 | 0.042 | 0.102 | Phosphodiesterase I inhibitor | | |
| 0.074 | 0.015 | 0.074 | Nicotinic alpha3beta2 receptor antagonist | | |
| 0.242 | 0.184 | 0.242 | Antibacterial | | |
| 0.121 | 0.064 | 0.121 | Cholesterol synthesis inhibitor | | |
| 0.061 | 0.004 | 0.061 | Nicotinic alpha3beta4 receptor agonist | | |
| 0.066 | 0.009 | 0.066 | Nicotinic acid receptor agonist | | |
| 0.065 | 0.009 | 0.065 | Alpha 1d adrenoreceptor agonist | | |
| 0.101 | 0.046 | 0.101 | Androgen antagonist | | |
| 0.161 | 0.106 | 0.161 | Death-associated protein kinase 3 inhibitor | | |
| 0.065 | 0.01 | 0.065 | GABA B receptor antagonist | | |
| 0.113 | 0.059 | 0.113 | Protein kinase C gamma inhibitor | | |
| 0.095 | 0.041 | 0.095 | Myeloperoxidase inhibitor | | |
| 0.11 | 0.056 | 0.11 | Carbonic anhydrase XV inhibitor | | |
| 0.091 | 0.037 | 0.091 | NMDA 2 receptor antagonist | | |
| 0.093 | 0.039 | 0.093 | Macrophage migration inhibitory factor inhibitor | | |
| 0.058 | 0.004 | 0.058 | CXC chemokine receptor agonist | | |
| 0.197 | 0.143 | 0.197 | Lipoxygenase inhibitor | | |
| 0.13 | 0.076 | 0.13 | Alkaline phosphatase inhibitor | | |
| 0.082 | 0.029 | 0.082 | Glutamate (mGluR) agonist | | |
| 0.067 | 0.014 | 0.067 | Potassium channel (Inward rectifier) activator | | |
| 0.101 | 0.048 | 0.101 | Bile acid receptor antagonist | | |
| 0.059 | 0.006 | 0.059 | Heme oxygenase inhibitor | | |
| 0.061 | 0.009 | 0.061 | Dihydrofolate reductase inhibitor | | |
| 0.06 | 0.008 | 0.06 | Purinergic P2X3 antagonist | | |
| 0.104 | 0.052 | 0.104 | Glutamate (mGluR7) agonist | | |
| 0.058 | 0.006 | 0.058 | Free fatty acid receptor 1 antagonist | | |
| 0.076 | 0.025 | 0.076 | Cyclin-dependent kinase 6 inhibitor | | |
| 0.098 | 0.047 | 0.098 | Pim-3 kinase inhibitor | | |
| 0.076 | 0.025 | 0.076 | Phosphodiesterase 1B inhibitor | | |
| 0.132 | 0.081 | 0.132 | Growth factor antagonist | | |
| 0.072 | 0.021 | 0.072 | Protein kinase C theta inhibitor | | |
| 0.063 | 0.013 | 0.063 | Potassium channel (ATP-sensitive) activator | | |
| 0.055 | 0.005 | 0.055 | Methionyl aminopeptidase 1 inhibitor | | |
| 0.059 | 0.009 | 0.059 | Histamine H1 receptor agonist | | |
| 0.128 | 0.079 | 0.128 | Tyrosine-protein kinase receptor antagonist | | |
| 0.09 | 0.041 | 0.09 | Estrogen-related receptor beta agonist | | |
| 0.136 | 0.087 | 0.136 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | | |
| 0.062 | 0.014 | 0.062 | Histamine H2 receptor agonist | | |
| 0.061 | 0.013 | 0.061 | Benzodiazepine antagonist | | |
| 0.17 | 0.122 | 0.17 | Antiamyloidogenic | | |
| 0.056 | 0.008 | 0.056 | MAP3K5 inhibitor | | |
| 0.079 | 0.032 | 0.079 | 5 Hydroxytryptamine 3A antagonist | | |
| 0.096 | 0.049 | 0.096 | Acetylcholine agonist | | |
| 0.064 | 0.017 | 0.064 | Glutamate (mGluR group III) agonist | | |
| 0.072 | 0.026 | 0.072 | Nicotinic neuronal receptor agonist | | |
| 0.107 | 0.061 | 0.107 | Vascular endothelial growth factor 1 antagonist | | |
| 0.126 | 0.08 | 0.126 | Cyclin-dependent kinase 7 inhibitor | | |
| 0.078 | 0.032 | 0.078 | Protein kinase C beta inhibitor | | |
| 0.083 | 0.037 | 0.083 | GABA B receptor agonist | | |
| 0.096 | 0.051 | 0.096 | Polo-like kinase-1 inhibitor | | |
| 0.124 | 0.078 | 0.124 | NADPH oxidase inhibitor | | |
| 0.05 | 0.004 | 0.05 | Nicotinic alpha4beta2 receptor agonist | | |
| 0.084 | 0.038 | 0.084 | Protein kinase B beta inhibitor | | |
| 0.062 | 0.016 | 0.062 | Potassium channel small-conductance Ca-activated blocker | | |
| 0.073 | 0.028 | 0.073 | Argininosuccinate synthase inhibitor | | |
| 0.095 | 0.05 | 0.095 | Ornithine decarboxylase inhibitor | | |
| 0.097 | 0.052 | 0.097 | Potassium channel activator | | |
| 0.053 | 0.009 | 0.053 | Calcium release-activated channel blocker | | |
| 0.093 | 0.048 | 0.093 | Bcr-Abl kinase inhibitor | | |
| 0.089 | 0.044 | 0.089 | Glycine receptor antagonist | | |
| 0.073 | 0.029 | 0.073 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | | |
| 0.092 | 0.047 | 0.092 | MAP-kinase-activated kinase inhibitor | | |
| 0.052 | 0.008 | 0.052 | Liver X receptor beta antagonist | | |
| 0.166 | 0.122 | 0.166 | Dyrk kinase inhibitor | | |
| 0.063 | 0.02 | 0.063 | Topoisomerase II beta inhibitor | | |
| 0.096 | 0.053 | 0.096 | Thioredoxin inhibitor | | |
| 0.241 | 0.198 | 0.241 | DNA polymerase beta inhibitor | | |
| 0.066 | 0.022 | 0.066 | AMPA receptor antagonist | | |
| 0.067 | 0.023 | 0.067 | Nicotinic receptor alpha7 subunit antagonist | | |
| 0.056 | 0.012 | 0.056 | Retinoid X alpha receptor agonist | | |
| 0.075 | 0.031 | 0.075 | Glutamate (mGluR6) antagonist | | |
| 0.067 | 0.023 | 0.067 | Dihydroorotate dehydrogenase inhibitor | | |
| 0.069 | 0.026 | 0.069 | Botulinum neurotoxin type A inhibitor | | |
| 0.052 | 0.009 | 0.052 | Endothelial nitric-oxide synthase inhibitor | | |
| 0.07 | 0.027 | 0.07 | Histone deacetylase SIRT3 inhibitor | | |
| 0.16 | 0.117 | 0.16 | Anticonvulsant | | |
| 0.055 | 0.012 | 0.055 | Angiotensin AT1 receptor antagonist | | |
| 0.061 | 0.019 | 0.061 | Aldosterone antagonist | | |
| 0.15 | 0.107 | 0.15 | Phospholipase C inhibitor | | |
| 0.109 | 0.067 | 0.109 | Alpha 2b adrenoreceptor antagonist | | |
| 0.069 | 0.028 | 0.069 | Potassium channel (Ca-activated) blocker | | |
| 0.046 | 0.004 | 0.046 | Alpha 2a adrenoreceptor agonist | | |
| 0.162 | 0.12 | 0.162 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | | |
| 0.159 | 0.118 | 0.159 | MAP kinase kinase 5 inhibitor | | |
| 0.068 | 0.026 | 0.068 | NMDA 2B receptor antagonist | | |
| 0.098 | 0.056 | 0.098 | Potassium channel (Voltage-sensitive) activator | | |
| 0.068 | 0.028 | 0.068 | Acyl-CoA dehydrogenase inhibitor | | |
| 0.106 | 0.065 | 0.106 | Falcipain 3 inhibitor | | |
| 0.08 | 0.04 | 0.08 | Vanilloid 4 agonist | | |
| 0.071 | 0.031 | 0.071 | Carbonic anhydrase stimulant | | |
| 0.089 | 0.049 | 0.089 | Histamine H1 receptor antagonist | | |
| 0.077 | 0.037 | 0.077 | Nav1.7 sodium channel blocker | | |
| 0.171 | 0.131 | 0.171 | ErbB-1 antagonist | | |
| 0.064 | 0.024 | 0.064 | Dihydroorotate oxidase inhibitor | | |
| 0.069 | 0.029 | 0.069 | Calcium channel P-type blocker | | |
| 0.122 | 0.082 | 0.122 | Sodium channel blocker | | |
| 0.052 | 0.012 | 0.052 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | | |
| 0.082 | 0.042 | 0.082 | MAP-kinase-activated kinase 2 inhibitor | | |
| 0.116 | 0.076 | 0.116 | Protein kinase (CK1) delta inhibitor | | |
| 0.072 | 0.032 | 0.072 | Interferon inducer | | |
| 0.121 | 0.082 | 0.121 | Nav1.2 sodium channel blocker | | |
| 0.077 | 0.038 | 0.077 | CDC7 inhibitor | | |
| 0.072 | 0.033 | 0.072 | Carbamoyl phosphate synthetase inhibitor | | |
| 0.056 | 0.018 | 0.056 | Benzodiazepine inverse agonist | | |
| 0.069 | 0.031 | 0.069 | Transcription factor AP-1 inhibitor | | |
| 0.054 | 0.016 | 0.054 | Retinoid X receptor agonist | | |
| 0.126 | 0.089 | 0.126 | CDC-like kinase 1 inhibitor | | |
| 0.185 | 0.148 | 0.185 | Neuropeptide Y2 antagonist | | |
| 0.054 | 0.017 | 0.054 | Urate transporter 1 inhibitor | | |
| 0.054 | 0.017 | 0.054 | Glutamate (mGluR group III) antagonist | | |
| 0.041 | 0.004 | 0.041 | Glucosylceramidase stimulant | | |
| 0.099 | 0.063 | 0.099 | Cyclin-dependent kinase 9 inhibitor | | |
| 0.129 | 0.093 | 0.129 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | | |
| 0.083 | 0.047 | 0.083 | Interferon agonist | | |
| 0.041 | 0.006 | 0.041 | MAP3K8 inhibitor | | |
| 0.053 | 0.018 | 0.053 | Guanylate cyclase stimulant | | |
| 0.059 | 0.024 | 0.059 | Purinergic P2X antagonist | | |
| 0.076 | 0.041 | 0.076 | Amidase inhibitor | | |
| 0.079 | 0.044 | 0.079 | Adenosine A3 receptor antagonist | | |
| 0.048 | 0.014 | 0.048 | Retinoid X receptor antagonist | | |
| 0.054 | 0.02 | 0.054 | Dihydroorotase inhibitor | | |
| 0.068 | 0.034 | 0.068 | TRPA1 antagonist | | |
| 0.044 | 0.01 | 0.044 | Uridine phosphorylase inhibitor | | |
| 0.086 | 0.053 | 0.086 | Histamine H2 receptor antagonist | | |
| 0.093 | 0.06 | 0.093 | Hepatocyte growth factor antagonist | | |
| 0.082 | 0.049 | 0.082 | Na+ K+ transporting ATPase inhibitor | | |
| 0.045 | 0.012 | 0.045 | Glutamate (mGluR4) agonist | | |
| 0.052 | 0.019 | 0.052 | Parathyroid hormone antagonist | | |
| 0.042 | 0.01 | 0.042 | Transforming growth factor beta 2 antagonist | | |
| 0.047 | 0.015 | 0.047 | Potassium channel Kv1.1 blocker | | |
| 0.093 | 0.061 | 0.093 | Protein kinase C zeta inhibitor | | |
| 0.045 | 0.013 | 0.045 | Potassium channel small-conductance Ca-activated activator | | |
| 0.048 | 0.017 | 0.048 | Vascular adhesion protein 1 inhibitor | | |
| 0.068 | 0.036 | 0.068 | Aromatase inhibitor | | |
| 0.051 | 0.02 | 0.051 | Glutamate (mGluR4) antagonist | | |
| 0.04 | 0.009 | 0.04 | Methionyl aminopeptidase 2 inhibitor | | |
| 0.12 | 0.088 | 0.12 | Vanilloid 1 agonist | | |
| 0.21 | 0.179 | 0.21 | Calpain 2 inhibitor | | |
| 0.097 | 0.066 | 0.097 | Carbonic anhydrase III inhibitor | | |
| 0.077 | 0.047 | 0.077 | Histone deacetylase SIRT1 stimulant | | |
| 0.077 | 0.047 | 0.077 | Histone deacetylase stimulant | | |
| 0.054 | 0.024 | 0.054 | Cholesterol esterase inhibitor | | |
| 0.114 | 0.084 | 0.114 | Toll-Like receptor 2 antagonist | | |
| 0.066 | 0.036 | 0.066 | 5 Hydroxytryptamine 5A antagonist | | |
| 0.053 | 0.023 | 0.053 | Nicotinic receptor alpha3 subunit antagonist | | |
| 0.061 | 0.03 | 0.061 | MAP kinase kinase 9 inhibitor | | |
| 0.13 | 0.1 | 0.13 | Neuropeptide Y1 antagonist | | |
| 0.065 | 0.035 | 0.065 | Enoyl-[acyl-carrier-protein] reductase inhibitor | | |
| 0.067 | 0.037 | 0.067 | NMDA 2C receptor antagonist | | |
| 0.042 | 0.012 | 0.042 | Retinoid X alpha receptor antagonist | | |
| 0.103 | 0.074 | 0.103 | Protein kinase (CK2) alpha inhibitor | | |
| 0.122 | 0.093 | 0.122 | Vascular endothelial growth factor 3 antagonist | | |
| 0.147 | 0.118 | 0.147 | Psychostimulant | | |
| 0.059 | 0.03 | 0.059 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | | |
| 0.041 | 0.013 | 0.041 | Angiotensin II receptor antagonist | | |
| 0.055 | 0.027 | 0.055 | Bromodomain-containing protein 3 inhibitor | | |
| 0.06 | 0.031 | 0.06 | Glucosylceramidase inhibitor | | |
| 0.048 | 0.021 | 0.048 | Liver X receptor alpha agonist | | |
| 0.053 | 0.025 | 0.053 | Glucose-6-phosphate isomerase inhibitor | | |
| 0.097 | 0.069 | 0.097 | Aurora-A kinase inhibitor | | |
| 0.11 | 0.083 | 0.11 | MAP kinase 12 inhibitor | | |
| 0.059 | 0.032 | 0.059 | Nicotinic alpha7 receptor agonist | | |
| 0.052 | 0.025 | 0.052 | Thymidylate synthase inhibitor | | |
| 0.045 | 0.018 | 0.045 | DNA gyrase subunit B inhibitor | | |
| 0.073 | 0.046 | 0.073 | Prostaglandin-E synthase inhibitor | | |
| 0.041 | 0.014 | 0.041 | Acetylcholine M4 receptor agonist | | |
| 0.072 | 0.046 | 0.072 | CXC chemokine receptor antagonist | | |
| 0.035 | 0.008 | 0.035 | Myristoyl transferase inhibitor | | |
| 0.063 | 0.037 | 0.063 | Cyclin D1 inhibitor | | |
| 0.04 | 0.015 | 0.04 | Tubulin agonist | | |
| 0.03 | 0.004 | 0.03 | Alpha 2b adrenoreceptor agonist | | |
| 0.053 | 0.028 | 0.053 | Nicotinic receptor alpha4 subunit antagonist | | |
| 0.044 | 0.019 | 0.044 | Diamine oxidase inhibitor | | |
| 0.058 | 0.034 | 0.058 | 5 Hydroxytryptamine 7 agonist | | |
| 0.229 | 0.205 | 0.229 | DNA directed DNA polymerase inhibitor | | |
| 0.051 | 0.027 | 0.051 | CC chemokine 4 receptor antagonist | | |
| 0.197 | 0.173 | 0.197 | Angiogenesis inhibitor | | |
| 0.141 | 0.118 | 0.141 | Cyclin-dependent kinase 3 inhibitor | | |
| 0.039 | 0.016 | 0.039 | Liver X receptor beta agonist | | |
| 0.054 | 0.031 | 0.054 | Diacylglycerol O-acyltransferase inhibitor | | |
| 0.074 | 0.051 | 0.074 | Glutamate decarboxylase inhibitor | | |
| 0.028 | 0.005 | 0.028 | Alpha 2c adrenoreceptor agonist | | |
| 0.028 | 0.005 | 0.028 | Toll-Like receptor 8 agonist | | |
| 0.027 | 0.004 | 0.027 | CC chemokine 9 receptor antagonist | | |
| 0.091 | 0.068 | 0.091 | Toll-Like receptor 3 antagonist | | |
| 0.126 | 0.104 | 0.126 | Tyrosine kinase inhibitor | | |
| 0.027 | 0.005 | 0.027 | Nicotinic alpha4 receptor agonist | | |
| 0.03 | 0.008 | 0.03 | Complement factor 1s inhibitor | | |
| 0.039 | 0.017 | 0.039 | Tryptophan 5 hydroxylase inhibitor | | |
| 0.043 | 0.021 | 0.043 | Protein kinase (CK1) epsilon inhibitor | | |
| 0.049 | 0.028 | 0.049 | Oleamide hydrolase inhibitor | | |
| 0.045 | 0.023 | 0.045 | Thymidine kinase inhibitor | | |
| 0.06 | 0.039 | 0.06 | Heat shock protein 90 beta antagonist | | |
| 0.039 | 0.019 | 0.039 | Glucose-dependent insulinotropic receptor agonist | | |
| 0.116 | 0.095 | 0.116 | Protein kinase (CK1) inhibitor | | |
| 0.03 | 0.01 | 0.03 | Acid ceramidase inhibitor | | |
| 0.055 | 0.036 | 0.055 | Thromboxane synthase inhibitor | | |
| 0.09 | 0.071 | 0.09 | Xanthine oxidase inhibitor | | |
| 0.042 | 0.023 | 0.042 | G protein-coupled receptor agonist | | |
| 0.06 | 0.041 | 0.06 | Raf kinase C inhibitor | | |
| 0.09 | 0.071 | 0.09 | MAO A inhibitor | | |
| 0.046 | 0.027 | 0.046 | AICAR transformylase inhibitor | | |
| 0.027 | 0.008 | 0.027 | Imidazoline I1 receptor antagonist | | |
| 0.023 | 0.005 | 0.023 | 5 Lipoxygenase activating protein inhibitor | | |
| 0.048 | 0.029 | 0.048 | Adenylate cyclase 1 inhibitor | | |
| 0.023 | 0.005 | 0.023 | Granulocyte colony stimulating factor receptor agonist | | |
| 0.027 | 0.009 | 0.027 | Glutaminyl-peptide cyclotransferase inhibitor | | |
| 0.027 | 0.009 | 0.027 | Hexokinase stimulant | | |
| 0.025 | 0.007 | 0.025 | Retinoid X beta receptor antagonist | | |
| 0.102 | 0.085 | 0.102 | Proteasome inhibitor | | |
| 0.091 | 0.074 | 0.091 | Alpha 2c adrenoreceptor antagonist | | |
| 0.057 | 0.04 | 0.057 | Tyrosine-protein kinase EMT inhibitor | | |
| 0.055 | 0.039 | 0.055 | Carbonic anhydrase VB inhibitor | | |
| 0.021 | 0.005 | 0.021 | Egl nine homolog 1 inhibitor | | |
| 0.15 | 0.134 | 0.15 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | | |
| 0.025 | 0.009 | 0.025 | Guanylate cyclase 1 stimulant | | |
| 0.133 | 0.117 | 0.133 | Antipruritic | | |
| 0.04 | 0.024 | 0.04 | Farnesoid X receptor agonist | | |
| 0.088 | 0.072 | 0.088 | Platelet activating factor beta antagonist | | |
| 0.066 | 0.051 | 0.066 | MDM2 inhibitor | | |
| 0.048 | 0.032 | 0.048 | Adenosine deaminase inhibitor | | |
| 0.053 | 0.038 | 0.053 | Cannabinoid CB2 receptor agonist | | |
| 0.187 | 0.173 | 0.187 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | | |
| 0.036 | 0.021 | 0.036 | Adenosine uptake inhibitor | | |
| 0.022 | 0.007 | 0.022 | Nicotinic acid receptor 1 antagonist | | |
| 0.048 | 0.034 | 0.048 | Histamine H4 receptor antagonist | | |
| 0.04 | 0.026 | 0.04 | CF transmembrane conductance regulator antagonist | | |
| 0.022 | 0.009 | 0.022 | Cyclin T1 inhibitor | | |
| 0.025 | 0.012 | 0.025 | Glutamate (mGluR1a) agonist | | |
| 0.024 | 0.011 | 0.024 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | | |
| 0.04 | 0.027 | 0.04 | GABA uptake inhibitor | | |
| 0.039 | 0.026 | 0.039 | Glutamate (mGluR group II) antagonist | | |
| 0.039 | 0.027 | 0.039 | Histone deacetylase 9 inhibitor | | |
| 0.057 | 0.045 | 0.057 | Androgen agonist | | |
| 0.017 | 0.005 | 0.017 | Egl nine homolog 3 inhibitor | | |
| 0.029 | 0.017 | 0.029 | Estrogen-related receptor gamma antagonist | | |
| 0.1 | 0.088 | 0.1 | Alkylator | | |
| 0.106 | 0.094 | 0.106 | Cyclooxygenase 3 inhibitor | | |
| 0.054 | 0.043 | 0.054 | Xanthine dehydrogenase inhibitor | | |
| 0.049 | 0.037 | 0.049 | Lysophosphatidic acid 3 receptor antagonist | | |
| 0.063 | 0.052 | 0.063 | Alpha adrenoreceptor agonist | | |
| 0.03 | 0.018 | 0.03 | 5 Hydroxytryptamine 6 agonist | | |
| 0.028 | 0.017 | 0.028 | Kynurenine 3 monooxygenase inhibitor | | |
| 0.045 | 0.034 | 0.045 | Purinergic P2X4 antagonist | | |
| 0.079 | 0.068 | 0.079 | Insulin growth factor antagonist | | |
| 0.038 | 0.027 | 0.038 | Glutamate (mGluR8) agonist | | |
| 0.033 | 0.022 | 0.033 | ATR kinase inhibitor | | |
| 0.089 | 0.079 | 0.089 | Insulin receptor antagonist | | |
| 0.087 | 0.076 | 0.087 | Sphingomyelinase inhibitor | | |
| 0.018 | 0.008 | 0.018 | CDK2/cyclin A3 inhibitor | | |
| 0.038 | 0.028 | 0.038 | 5 Hydroxytryptamine 2B agonist | | |
| 0.026 | 0.016 | 0.026 | Vanilloid 2 agonist | | |
| 0.035 | 0.025 | 0.035 | Phosphoglycerate kinase inhibitor | | |
| 0.015 | 0.006 | 0.015 | Cyclin D2 inhibitor | | |
| 0.068 | 0.059 | 0.068 | Acetylcholine M4 receptor antagonist | | |
| 0.029 | 0.021 | 0.029 | Glutamate (mGluR2) antagonist | | |
| 0.057 | 0.048 | 0.057 | Ryanodine receptor antagonist | | |
| 0.095 | 0.087 | 0.095 | Vascular endothelial growth factor antagonist | | |
| 0.047 | 0.038 | 0.047 | Phosphatidylinositol 3-kinase beta inhibitor | | |
| 0.076 | 0.067 | 0.076 | Insulin like growth factor 1 antagonist | | |
| 0.027 | 0.018 | 0.027 | Nicotinic acid receptor 2 antagonist | | |
| 0.026 | 0.019 | 0.026 | Thymidine kinase (Herpes simplex virus 1) inhibitor | | |
| 0.029 | 0.021 | 0.029 | Liver X receptor alpha antagonist | | |
| 0.085 | 0.078 | 0.085 | Check point kinase 2 inhibitor | | |
| 0.025 | 0.018 | 0.025 | Prostaglandin H2 antagonist | | |
| 0.036 | 0.029 | 0.036 | Delayed rectifier potassium channel blocker | | |
| 0.052 | 0.046 | 0.052 | 5 Hydroxytryptamine 6 antagonist | | |
| 0.012 | 0.006 | 0.012 | Imidazoline I2 receptor antagonist | | |
| 0.062 | 0.056 | 0.062 | HIV-1 reverse transcriptase inhibitor | | |
| 0.057 | 0.051 | 0.057 | Cannabinoid receptor agonist | | |
| 0.026 | 0.019 | 0.026 | Thymidine phosphorylase inhibitor | | |
| 0.104 | 0.098 | 0.104 | Ca2+/calmodulin-dependent kinase II delta inhibitor | | |
| 0.039 | 0.033 | 0.039 | Kainate receptor agonist | | |
| 0.037 | 0.031 | 0.037 | Dihydropteroate synthase inhibitor | | |
| 0.038 | 0.032 | 0.038 | CDK5/p25 inhibitor | | |
| 0.139 | 0.133 | 0.139 | Non-steroidal antiinflammatory agent | | |
| 0.047 | 0.042 | 0.047 | mTOR inhibitor | | |
| 0.034 | 0.029 | 0.034 | Glutamate (mGluR3) antagonist | | |
| 0.128 | 0.122 | 0.128 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | | |
| 0.027 | 0.022 | 0.027 | Purinergic P2Y15 antagonist | | |
| 0.05 | 0.045 | 0.05 | Heparanase inhibitor | | |
| 0.164 | 0.159 | 0.164 | MAP-kinase-activated kinase 5 inhibitor | | |
| 0.021 | 0.016 | 0.021 | Alpha 2d adrenoreceptor agonist | | |
| 0.09 | 0.086 | 0.09 | AMP-activated protein kinase stimulant | | |
| 0.013 | 0.009 | 0.013 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | | |
| 0.033 | 0.029 | 0.033 | Inosine monophosphate dehydrogenase inhibitor | | |
| 0.059 | 0.056 | 0.059 | Toll-Like receptor 7 antagonist | | |
| 0.048 | 0.044 | 0.048 | Histamine agonist | | |
| 0.098 | 0.095 | 0.098 | Caspase 3 inhibitor | | |
| 0.031 | 0.028 | 0.031 | Carboxypeptidase B inhibitor | | |
| 0.007 | 0.004 | 0.007 | CC chemokine 6 receptor agonist | | |
| 0.068 | 0.065 | 0.068 | GABA aminotransferase inhibitor | | |
| 0.054 | 0.051 | 0.054 | Cyclin A1 inhibitor | | |
| 0.007 | 0.005 | 0.007 | DNA topoisomerase III inhibitor | | |
| 0.026 | 0.024 | 0.026 | CDK4/cyclin D3 inhibitor | | |
| 0.055 | 0.053 | 0.055 | 5 Hydroxytryptamine 2A agonist | | |
| 0.099 | 0.097 | 0.099 | Calcium channel N-type blocker | | |
| 0.061 | 0.059 | 0.061 | Carbonic anhydrase VA inhibitor | | |
| 0.032 | 0.03 | 0.032 | Benzodiazepine receptor peripheral-type antagonist | | |
| 0.134 | 0.132 | 0.134 | Ca2+/calmodulin-dependent protein kinase inhibitor | | |
| 0.087 | 0.085 | 0.087 | Mediator release inhibitor | | |
| 0.101 | 0.1 | 0.101 | Sphingosine 1-phosphate receptor 2 agonist | | |
| 0.04 | 0.039 | 0.04 | Fructose-1,6-bisphosphatase inhibitor | | |
| 0.028 | 0.027 | 0.028 | Epoxide hydrolase 1 inhibitor | | |
| 0.085 | 0.084 | 0.085 | Vascular endothelial growth factor 2 antagonist | | |
| 0.03 | 0.029 | 0.03 | Fumarate hydratase inhibitor | | |
| 0.03 | 0.029 | 0.03 | Vanilloid 4 antagonist | | |